KMPH KEMPHARM INC

KemPharm to Present at Two Healthcare Investor Conferences During September 2018

KemPharm to Present at Two Healthcare Investor Conferences During September 2018

CORALVILLE, Iowa, Sept. 05, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis C. Mickle, Ph.D., will present at the Janney Montgomery Scott Healthcare Conference being held September 17-18, 2018.  He will also attend one-on-one investor meetings at the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease, to be held September 26-27, 2018.  Both conferences are in New York City.

Details of KemPharm's presentation and one-on-one investor meetings are as follows:

Conference:     Janney Montgomery Scott Healthcare Conference 2018

Date:                Monday, September 17, 2018

Time:                9:55 am (ET)

Location:          Union League Club, 38 East 37th Street, New York, NY 10016

Conference:     Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease

Date:                Wednesday, September 26, 2018

Time:                8:00 am to 5:00 pm (ET)

Location:          The Langham, 400 Fifth Avenue, New York, NY 10018

The Janney Healthcare Conference presentation will be webcast and available on the Investor Relations section under “Events & Presentations” on the Company's website at .

About KemPharm

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) platform technology.  KemPharm utilizes its proprietary LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD.  In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.  For more information on KemPharm and its pipeline of prodrug product candidates visit or connect with us on , , and .

Investor/Media Contacts:   
Jason Rando / Joshua Drumm, Ph.D.



212-375-2665 / 2664





 		 
EN
05/09/2018

Underlying

KMPHKEMPHARM INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on KEMPHARM INC

 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics Begins Trading as ZVRA

Zevra Therapeutics Begins Trading as ZVRA Company’s common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol “ZVRA” starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol “ZVRA” on the Nasdaq Global Selec...

March 1, 2023 1 EN
 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as ...

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD) CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that im...

February 28, 2023 1 EN
 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Prelimi...

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2023 Annual Meeting of Stockholders (“Annual Meeting”), which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this...

February 27, 2023 1 EN
 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022. The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company’s website, ....

February 27, 2023 1 EN
 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Post...

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023 Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company,” formerly known as KemPharm, Inc.), today announced that arimoclomol, the Company’s orally-delivered, first-in-class investigational product candidate being developed a...

February 24, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch